Atossa Therapeutics (NASDAQ: ATOS)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-12 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.050 | -0.040 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Atossa Therapeutics (NASDAQ: ATOS) through any online brokerage.
Other companies in Atossa Therapeutics’s space includes: CytomX Therapeutics (NASDAQ:CTMX), Adverum Biotechnologies (NASDAQ:ADVM), Celcuity (NASDAQ:CELC), Immuneering (NASDAQ:IMRX) and Humanigen (NASDAQ:HGEN).
The latest price target for Atossa Therapeutics (NASDAQ: ATOS) was reported by Ascendiant Capital on Thursday, September 17, 2020. The analyst firm set a price target for 7.00 expecting ATOS to rise to within 12 months (a possible 593.07% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Atossa Therapeutics (NASDAQ: ATOS) is $1.01 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Atossa Therapeutics.
Atossa Therapeutics’s Q2 earnings are confirmed for Friday, August 12, 2022.
There is no upcoming split for Atossa Therapeutics.
Atossa Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.